ASPEN PHARMACARE HOLDINGS LIMITED - Use of Dexamethasone in the clinical management of patients with COVID-19 requiring respiratory intervention
Use of Dexamethasone in the clinical management of patients with COVID-19 requiring respiratory intervention
ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)
USE OF DEXAMETHASONE IN THE TREATMENT OF PATIENTS WITH COVID-19 REQUIRING RESPIRATORY
INTERVENTION
To ensure the equal distribution of information which may possibly be price sensitive, Aspen has noted the
preliminary results of a drug trial using dexamethasone in the treatment of patients with COVID-19
requiring respiratory intervention and the related media coverage. It is confirmed that Aspen owns rights to
this product and distributes both injectables and/or tablets containing dexamethasone in a number of
countries. Aspen markets an injectable dexamethasone in South Africa, which is manufactured locally by a
third party.
Durban
17 June 2020
Sponsor
Investec Bank Limited
Date: 17-06-2020 10:42:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
